Inhaled heparin in pneumonia
Phase 2
- Conditions
- VENTILATOR ASSOCIATED PNEUMONIA(VAP).Ventilator associated pneumoniaJ95.851
- Registration Number
- IRCT20140310016917N8
- Lead Sponsor
- Vice chancellor for research of Guilan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Patients are included in the study according to the score of the severity of pulmonary infection index (>=6) and age above 18 years old.
Exclusion Criteria
Mechanical ventilation less than 48 h during hospitalization
Cancer and immunedeficient patients
chronic infection and coinfection in other sites of body
Do not resuscisate patients
CRRT dependency
Theraputic dose of any anticoagulants
BMI>40
History of allergy to heparin and HIT
History of bleeding in 3 month ago and bleeding tendency
ICH in 1year ago
possibility of epidural catheter insertion during next 48 h
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration of antibiotic therapy. Timepoint: Every other day, procalcitonin is measured to determine the length of antibiotic treatment. Method of measurement: Procalcitonin Measuring Kit.
- Secondary Outcome Measures
Name Time Method Clinical pulmonary infection severity score. Timepoint: On admission and daily. Method of measurement: Clinical Information Collection Form.;C Reactive Protein. Timepoint: On admission then daily. Method of measurement: Clinical Information Collection Form.;Sepsis Organ Failure Assessment score. Timepoint: On admission then daily. Method of measurement: Clinical Information Collection Form.;Acute Physiologic And Chronic Health Evaluation II score. Timepoint: on addmision then daily. Method of measurement: Clinical Information Collection Form.